Please check your internet connection and try again.
# Lorazepam
## Overview
Lorazepam is a benzodiazepine with anxiolytic, sedative, amnestic, anticonvulsant, and muscle relaxant properties. It is primarily used for the short-term management of anxiety disorders and insomnia.
## Primary Indications
* Management of anxiety disorders
* Short-term relief of insomnia
* Premedication for surgical procedures
* Management of status epilepticus (IV/IM)
* Management of acute agitation
## Adult Dosing
* **Anxiety Disorders:** 0.5 mg to 2 mg three times daily. Maximum daily dose generally 10 mg.
* **Insomnia:** 2 mg to 4 mg at bedtime.
* **Premedication:** 2 mg to 4 mg IM administered 2 hours before surgery, or 0.05 mg/kg (up to 4 mg) IV administered 15-30 minutes before surgery.
* **Status Epilepticus:** 4 mg IV or IM. Repeat in 5-10 minutes if seizures persist, not to exceed 8 mg.
## Pediatric Dosing
Dosing in pediatric patients is not well-established and should be individualized based on response and tolerance.
* **Anxiety:** Extrapolation from adult data suggests starting doses of 0.02-0.05 mg/kg/dose every 8-12 hours.
* **Status Epilepticus:** 0.1 mg/kg IV or IM, not to exceed 4 mg per dose. May repeat in 5-10 minutes.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. No specific dose adjustments are routinely recommended, but lower doses may be appropriate.
* **Renal Impairment:** No specific dose adjustments are routinely recommended.
* **Elderly:** Reduce initial doses by 25-50% and titrate cautiously.
## Contraindications
* Hypersensitivity to lorazepam, other benzodiazepines, or any component of the formulation.
* Acute narrow-angle glaucoma.
* Severe respiratory insufficiency.
* Severe hepatic insufficiency.
* Myasthenia gravis.
* Sleep apnea.
## Adverse Effects
* **Common:** Drowsiness, dizziness, weakness, unsteadiness, cognitive impairment.
* **Serious:** Respiratory depression, paradoxical reactions (e.g., agitation, excitement), dependence and withdrawal symptoms.
## Key Drug Interactions
* **CNS Depressants (alcohol, opioids, other sedatives):** Additive CNS depression, potentially leading to severe sedation, respiratory depression, coma, and death.
* **CYP3A4 Inhibitors/Inducers:** Lorazepam is metabolized via glucuronidation, not primarily by CYP enzymes, so clinically significant interactions are less common compared to other benzodiazepines. However, some agents may affect lorazepam metabolism or excretion indirectly.
* **Valproic acid:** May increase lorazepam plasma concentrations.
## Monitoring
* Signs and symptoms of sedation and respiratory depression, especially with IV administration.
* Effectiveness in treating anxiety or insomnia.
* Signs of dependence or withdrawal upon discontinuation.
* Cognitive function and functional status.
## Clinical Pearls
* Lorazepam has a relatively intermediate half-life.
* For IV administration, dilute with an equal volume of sterile water for injection, 0.9% sodium chloride, or 5% dextrose injection to minimize vein irritation and precipitation. Do not mix with other medications in the same syringe.
* Abrupt discontinuation can lead to withdrawal symptoms, including rebound insomnia, anxiety, and potentially seizures. Tapering is recommended.
* Use in pregnancy is associated with risks, including neonatal withdrawal and floppy infant syndrome.
---
*This information is intended for healthcare professionals. Always consult the current prescribing information and relevant clinical guidelines for complete details before making treatment decisions.*
